Editor's note - Page 7 of 19 - Express Pharma

Why API price needs to be part of NPPA’s pricing formula

Will regulators catch up in 2020?

Rationalising pharma trade margins seems next on the list

Lupin sells stakes in Kyowa but its not a Sayonara

After sartans and ranitidine, where will NDMA show up next?

Slaying GMP non-compliance woes

Heeding the clarion call for sustainability

Price caps are a band aid hiding larger issues

CDSCO is blowin’ in the wind

Big Pharma to get bigger, but what about patients?